Abstract
Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990.
©2022 American Association for Cancer Research.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Cell Line, Tumor
-
Deoxycytidine / analogs & derivatives
-
Gemcitabine
-
Glucocorticoid-Induced TNFR-Related Protein / immunology
-
Humans
-
Neoplasms* / metabolism
-
Nivolumab*
-
T-Lymphocytes, Regulatory / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Glucocorticoid-Induced TNFR-Related Protein
-
Deoxycytidine
-
Nivolumab
-
pembrolizumab
-
Gemcitabine